OpenLB
Open Library of Bioscience
Advanced Search
Biomolecules
Feb 01, 2025;15 (2):

Quinazolinones as Potential Anticancer Agents: Synthesis and Action Mechanisms.

Zhijiang Deng, Jieming Li, Pengbo Zhu, Jie Wang, Yuanfang Kong, Yulong Hu, Juntao Cai, Chunhong Dong
Author Information
  1. Zhijiang Deng: Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China.
  2. Jieming Li: Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China. ORCID
  3. Pengbo Zhu: Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China.
  4. Jie Wang: Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China.
  5. Yuanfang Kong: Henan Polysaccharide Research Center, Zhengzhou 450046, China. ORCID
  6. Yulong Hu: Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China.
  7. Juntao Cai: Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China.
  8. Chunhong Dong: Traditional Chinese Medicine (Zhong Jing) School, Henan University of Chinese Medicine, Zhengzhou 450046, China.
PMID: 40001513 DOI: 10.3390/biom15020210

Abstract

Quinazolinones, essential quinazoline derivatives, exhibit diverse biological activities with applications in pharmaceuticals and insecticides. Some derivatives have already been developed as commercial drugs. Given the rising cancer incidence, there is a critical need for new anticancer agents, and quinazolinones show promising potential in this domain. The present review focuses on novel advances in the synthesis of these important scaffolds and other medicinal aspects involving drug design, the structure-activity relationship, and action mechanisms of quinazoline and quinazolinone derivatives, to help in the development of new quinazoline and quinazolinone derivatives.

Keywords

anticancer catalytic synthesis mechanisms quinazolinones

References

Bioorg Chem. 2023 Feb;131:106310 [PMID: 36528923]
Bioorg Med Chem Lett. 2005 Apr 1;15(7):1915-7 [PMID: 15780632]
Mol Med Rep. 2019 Apr;19(4):2890-2896 [PMID: 30720138]
Eur J Med Chem. 2015 May 5;95:492-9 [PMID: 25847767]
Agents Actions. 1986 Jun;18(3-4):313-7 [PMID: 2428219]
Front Chem. 2022 Nov 17;10:969559 [PMID: 36465863]
Drug Dev Res. 2022 Jun;83(4):859-890 [PMID: 35297084]
Toxicol Rep. 2014 Aug 12;1:1013-1025 [PMID: 28962314]
J Enzyme Inhib Med Chem. 2023 Dec;38(1):2199166 [PMID: 37038884]
Chem Biodivers. 2022 Jun;19(6):e202200189 [PMID: 35510593]
Org Biomol Chem. 2008 Jul 21;6(14):2499-506 [PMID: 18600270]
Bioorg Med Chem Lett. 2001 Jan 22;11(2):177-81 [PMID: 11206453]
Sci Rep. 2022 Dec 14;12(1):21599 [PMID: 36517571]
J Org Chem. 2021 Sep 3;86(17):12257-12266 [PMID: 34387487]
Eur J Med Chem. 2019 May 15;170:157-172 [PMID: 30884322]
Arch Pharm (Weinheim). 2023 Jan;356(1):e2200417 [PMID: 36257809]
Org Lett. 2022 Nov 4;24(43):7912-7917 [PMID: 36269864]
Org Lett. 2016 Feb 19;18(4):824-7 [PMID: 26853471]
J Pharm Pharmacol. 1981 Apr;33(4):219-22 [PMID: 6115903]
Food Chem Toxicol. 2016 Jan;87:1-11 [PMID: 26615871]
Nat Prod Res. 2024 Nov 9;:1-6 [PMID: 39520723]
J Org Chem. 2018 Nov 16;83(22):14138-14145 [PMID: 30359521]
Bioorg Chem. 2024 Mar;144:107086 [PMID: 38219478]
Molecules. 2018 Jul 12;23(7): [PMID: 30002297]
Gut. 2022 Jan;71(1):119-128 [PMID: 33436496]
J Org Chem. 2021 Nov 5;86(21):15117-15127 [PMID: 34619960]
Res Pharm Sci. 2017 Aug;12(4):290-298 [PMID: 28855940]
Arch Pharm (Weinheim). 2013 Aug;346(8):610-7 [PMID: 23873839]
Rheumatol Rehabil. 1982 May;21(2):98-100 [PMID: 7043713]
Chem Biodivers. 2024 Nov 14;:e202401768 [PMID: 39540225]
BMC Chem. 2022 May 18;16(1):35 [PMID: 35585608]
Chem Cent J. 2017 Mar 15;11:23 [PMID: 28360932]
Bioorg Med Chem. 2021 Sep 1;45:116312 [PMID: 34332211]
Cancers (Basel). 2022 May 16;14(10): [PMID: 35626056]
Chem Cent J. 2013 Jun 03;7(1):95 [PMID: 23731671]
J Res Med Sci. 2022 Sep 27;27:68 [PMID: 36353342]
RSC Adv. 2020 Apr 17;10(26):15354-15359 [PMID: 35495457]
Pharmacol Res. 2019 Mar;141:541-550 [PMID: 30616017]
J Org Chem. 2018 Sep 7;83(17):10352-10358 [PMID: 30084636]
Biochim Biophys Acta. 2014 Jul;1840(7):2310-20 [PMID: 24594224]
Int J Med Chem. 2014;2014:395637 [PMID: 25692041]
Eur J Med Chem. 2017 Dec 1;141:84-91 [PMID: 29028534]
Eur J Med Chem. 2024 Nov 5;277:116766 [PMID: 39163776]
Bioorg Med Chem. 2023 Apr 15;84:117261 [PMID: 37011446]
Bioorg Med Chem Lett. 2012 Mar 1;22(5):1879-85 [PMID: 22326394]
Clin Cancer Res. 2013 Jul 1;19(13):3533-44 [PMID: 23674493]
J Org Chem. 2018 Aug 17;83(16):9201-9209 [PMID: 29961318]
J Org Chem. 2015 Oct 2;80(19):9392-400 [PMID: 26339716]
J Org Chem. 2018 Jun 15;83(12):6719-6727 [PMID: 29771521]
Chem Rev. 2015 May 13;115(9):3170-387 [PMID: 25751710]
Anticancer Res. 2021 Jan;41(1):259-268 [PMID: 33419820]
ChemSusChem. 2019 Jul 5;12(13):3043-3048 [PMID: 30791215]
J Nat Prod. 1999 Apr;62(4):650-2 [PMID: 10217735]
Inflammopharmacology. 2018 Dec;26(6):1441-1453 [PMID: 29663100]
RSC Adv. 2022 Aug 2;12(33):21340-21352 [PMID: 35975048]
Bioorg Med Chem. 2018 May 15;26(9):2199-2220 [PMID: 29681487]
J Org Chem. 2019 Mar 1;84(5):2798-2807 [PMID: 30740976]
J Enzyme Inhib Med Chem. 2017 Dec;32(1):893-907 [PMID: 28661197]
J Org Chem. 2015 Jul 2;80(13):6915-21 [PMID: 26067767]
Ann Oncol. 2019 Dec 1;30(Suppl_10):x12-x20 [PMID: 31859349]
Clin Colorectal Cancer. 2021 Jun;20(2):e75-e81 [PMID: 33268287]
Sci Rep. 2015 Jun 25;5:11544 [PMID: 26108872]
RSC Adv. 2023 Sep 18;13(39):27657-27662 [PMID: 37727584]
Org Lett. 2020 Jul 17;22(14):5567-5571 [PMID: 32610908]
J Org Chem. 2021 Nov 5;86(21):14866-14882 [PMID: 34624963]
Molecules. 2023 Apr 04;28(7): [PMID: 37049989]
Nat Cell Biol. 2013 Jun;15(6):637-46 [PMID: 23708000]
N Engl J Med. 2018 Nov 22;379(21):2052-2062 [PMID: 30462943]
J Org Chem. 2014 Jun 6;79(11):5082-7 [PMID: 24810598]
Cent Nerv Syst Agents Med Chem. 2014;14(1):34-8 [PMID: 25174978]
Clin Cancer Res. 2010 Jan 15;16(2):566-76 [PMID: 20068098]
J Org Chem. 2015 Jul 17;80(14):7099-107 [PMID: 26098660]
J Org Chem. 2016 Jun 17;81(12):5046-55 [PMID: 27223462]
Nat Rev Cancer. 2020 Mar;20(3):174-186 [PMID: 31980749]
Neuropharmacology. 2014 Nov;86:219-27 [PMID: 25107587]
Eur J Med Chem. 2023 Jan 5;245(Pt 1):114912 [PMID: 36395650]
Curr Top Med Chem. 2022;22(12):1035-1044 [PMID: 35255796]
Eur J Med Chem. 2004 Apr;39(4):299-304 [PMID: 15072839]
J Pharmacol Exp Ther. 2010 Aug;334(2):477-88 [PMID: 20463006]
Int J Oncol. 1999 Dec;15(6):1245-50 [PMID: 10568835]
Chem Commun (Camb). 2024 Jul 4;60(55):7097-7100 [PMID: 38899802]
Chem Commun (Camb). 2012 Apr 21;48(32):3836-8 [PMID: 22436843]
J Enzyme Inhib Med Chem. 2020 Dec;35(1):1953-1963 [PMID: 33143469]
Chem Cent J. 2017 Oct 13;11(1):102 [PMID: 29086906]
Biomolecules. 2024 Feb 12;14(2): [PMID: 38397456]
Cardiology. 2014;127(1):20-4 [PMID: 24192670]
Cancer Cell. 2023 Mar 13;41(3):374-403 [PMID: 36917948]
Eur J Med Chem. 2015 Jan 27;90:124-69 [PMID: 25461317]
Molecules. 2023 Mar 28;28(7): [PMID: 37049762]
N Engl J Med. 2014 Mar 13;370(11):997-1007 [PMID: 24450857]
Ann Oncol. 2020 Jan;31(1):30-40 [PMID: 31912793]
Bioorg Chem. 2020 Jan;94:103422 [PMID: 31812261]
J Enzyme Inhib Med Chem. 2017 Dec;32(1):935-944 [PMID: 28718672]
Future Med Chem. 2023 Feb;15(3):275-290 [PMID: 36891994]
J Med Chem. 2023 Feb 9;66(3):1941-1954 [PMID: 36719971]
Molecules. 2023 Sep 13;28(18): [PMID: 37764382]
Molecules. 2022 Dec 05;27(23): [PMID: 36500678]
J Org Chem. 2015 May 1;80(9):4736-42 [PMID: 25849218]
Sci Rep. 2024 Feb 12;14(1):3530 [PMID: 38347004]
Nat Rev Immunol. 2017 May;17(5):333-340 [PMID: 28163302]
Eur J Med Chem. 2019 Mar 1;165:115-132 [PMID: 30665142]
J Enzyme Inhib Med Chem. 2020 Dec;35(1):555-564 [PMID: 31967481]
Mini Rev Med Chem. 2022;22(16):2146-2165 [PMID: 35114920]
BMC Chem. 2022 Dec 2;16(1):107 [PMID: 36461074]
Mol Cancer Ther. 2006 Dec;5(12):3001-13 [PMID: 17172404]
Org Lett. 2021 Feb 5;23(3):1026-1031 [PMID: 33464096]
Bioorg Med Chem. 2017 Feb 15;25(4):1496-1513 [PMID: 28117121]
Int J Mol Sci. 2023 Jul 12;24(14): [PMID: 37511135]
RSC Adv. 2020 Mar 4;10(16):9486-9491 [PMID: 35497232]
Rejuvenation Res. 2021 Jun;24(3):181-190 [PMID: 32892706]
Int J Mol Sci. 2020 Sep 29;21(19): [PMID: 33003448]
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1205-1216 [PMID: 34074193]
Adv Biol (Weinh). 2024 Jan;8(1):e2300060 [PMID: 37821359]
Beilstein J Org Chem. 2015 Nov 19;11:2252-3 [PMID: 26664648]
Drug Discov Today. 2022 Sep;27(9):2586-2592 [PMID: 35636724]
J Org Chem. 2020 Jun 5;85(11):7378-7385 [PMID: 32400159]
J Med Chem. 2018 Feb 8;61(3):1031-1044 [PMID: 29227648]
ACS Med Chem Lett. 2013 Jan 17;4(2):288-92 [PMID: 24900660]
Org Lett. 2018 Nov 16;20(22):7107-7112 [PMID: 30407020]
J Org Chem. 2022 Aug 5;87(15):9864-9874 [PMID: 35834782]

Grants

  1. 2021M690936/China Postdoctoral Science Foundation
  2. 22A350003/the plan for the Key Scientific Research Foundation of the Higher Education Institutions of Henan Province
  3. 232300421374/Natural Science Foundation of Henan Province
  4. 224070427/National Natural Science Foundation of China

MeSH Term

Humans
Quinazolinones
Antineoplastic Agents
Structure-Activity Relationship
Neoplasms
Animals
Drug Design
Quinazolines

Chemicals

Quinazolinones
Antineoplastic Agents
Quinazolines
Journal Article Review

Word Cloud

Similar Articles

Cited By